Previous 10 | Next 10 |
WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated,...
C4 Therapeutics press release (NASDAQ:CCCC): Q1 GAAP EPS of -$0.65 misses by $0.06. Revenue of $7.65M (+3.0% Y/Y) misses by $0.4M. Shares -2.51% PM. For further details see: C4 Therapeutics GAAP EPS of -$0.65 misses by $0.06, revenue of $7.65M misses by $0.4M
– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in Cohorts B1 and C – – Phase 1/2 Clinical Trial Initiated for CFT8634, a BRD9 Degrader, for Patients with Synovia...
CCCC showed a lot of preclinical promise for its protein degrader platform. However, first clinical data presented at AACR has destroyed the stock. It may recover, but I can't bet on that happening in this bear market. For further details see: C4 Therapeutics: Poor Data ...
Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto Holding (MSP) +21%. Axcella Health (AXLA) +16%. TScan Therapeutic...
After a decline of more than 60% last week, the clinical-stage biotech, C4 Therapeutics (NASDAQ:CCCC), continues to trade lower on Monday as the market reacts to the company’s Phase 1/2 data for its lead candidate, CFT7455 from a group of patients with multiple myeloma. C4 (CCCC) ...
With investors worried about a murky economic future, the major U.S. equity averages posted a mixed performance on Friday. Weakness in tech drove the Nasdaq and S&P 500 lower, while the Dow scratched out a modest gain. Semiconductor makers contributed to the slide in technology, with Trui...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
The shares of C4 Therapeutics (NASDAQ:CCCC) lost more than half of their value on Friday after the clinical-stage biotech disclosed data from a group of multiple myeloma (MM) patients taking part in its Phase 1/2 clinical trial for the lead asset, CFT7455. The first cohort of the study involv...
– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies – – CFT7455 Exhibits Differentiated Pharmacokinetics (PK) and Potency Relative ...
News, Short Squeeze, Breakout and More Instantly...
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...